<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.1d1" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher">Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)</journal-id><journal-title-group><journal-title>Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)</journal-title></journal-title-group><issn publication-format="electronic">1990-472X</issn><publisher><publisher-name>Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">11598</article-id><article-id pub-id-type="doi">10.18499/1990-472X-2026-27-1-%p</article-id><article-categories><subj-group subj-group-type="heading"><subject>Unclassified</subject></subj-group></article-categories><title-group><article-title>The role of immunomodulation in the correction of a disadaptive immune response in patients with infectious exacerbation of chronic obstructive pulmonary disease</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kupriyanova</surname><given-names>Arina</given-names></name><bio>&lt;p&gt;Assistant Professor of Infectious Diseases and Clinical Immunology&lt;/p&gt;</bio><email>arina.kupriyanova.2000@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Krasnorutskaya</surname><given-names>Olga</given-names></name><bio>&lt;p&gt;MD, Head of the Department of Infectious Diseases and Clinical Immunology&lt;/p&gt;</bio><email>lech@vrngmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bugrimov</surname><given-names>Daniil</given-names></name><bio>&lt;p&gt;PhD, Associate Professor of Pathological Anatomy&lt;/p&gt;</bio><email>patanat@vrngmu.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff id="aff-1">ФГБОУ ВО ВГМУ им. Н.Н. Бурденко Минздрава России</aff><pub-date date-type="epub" iso-8601-date="2026-04-06" publication-format="electronic"><day>06</day><month>04</month><year>2026</year></pub-date><volume>27</volume><issue>1</issue><history><pub-date date-type="received" iso-8601-date="2026-04-03"><day>03</day><month>04</month><year>2026</year></pub-date></history><permissions><copyright-statement>Copyright © 2026, Medical Scientific Bulletin of Central Chernozemye (Naučno-medicinskij vestnik Centralʹnogo Černozemʹâ)</copyright-statement><copyright-year>2026</copyright-year></permissions><abstract>&lt;p&gt;The article analyzes the role of disadaptive trained immunity in the pathogenesis of chronic obstructive pulmonary disease and the formation of antibiotic resistance during infectious exacerbations of the disease. The results of a prospective comparative study involving 60 patients with stage IIIII COPD, divided into a main group and a control group of 30 people each, are presented. It was shown that the inclusion of sodium deoxyribonucleate in the standard treatment regimen was accompanied by a more pronounced clinical improvement: an increase in saturation to 97% versus 95% in the control (p=0.015), a decrease in cough intensity (p=0.001), and normalization of sputum rheology. A significant correction of the immune response was noted, manifested by a decrease in IL-8 levels from 12.52.3 to 5.41.36 pg/ml (p0.001) and an increase in -interferon from 6.60.8 to 8.81.1 pg/ml (p0.01). The proportion of resistant strains decreased from 40% to 10.3% (p0.001), and the microbial load decreased from 10⁶ to&lt;/p&gt;&#13;
&lt;p&gt;5.510 CFU/ml (p0.001). The obtained data confirm the effectiveness of the immunocorrective approach in the complex therapy of COPD.&lt;/p&gt;</abstract><kwd-group xml:lang="en"><kwd>сhronic obstructive pulmonary disease (COPD), trained immunity, maladaptive immunity, sodium deoxyribonucleate, antibiotic resistance, and immunomodulatory therapy.</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>хроническая обструктивная болезнь лёгких (ХОБЛ), тренированный иммунитет, дезадаптивный иммунитет, дезоксирибонуклеат натрия, антибиотикорезистентность, иммуномодулирующая терапия.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1.	Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2024 Report) URL: https://goldcopd.org/ (дата обращения: 11.02.2026).</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2.	Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary / A. Agustí, B.R. Celli, G.J. Criner [et al.] // European Respiratory Journal. – 2023. – Vol. 61,</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>№ 4. – P. 2300239.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>3.	Advocating the role of trained immunity in the pathogenesis of ME/CFS: a mini review / B. Humer, W. A. Dik, M. A. Versnel // Frontiers in Immunology. – 2025. – Vol. 16. – P. 1483764. – DOI: 10.3389/fimmu.2025.1483764.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>4.	Trained immunity in the lung / E. Idiiatullina, D. Parker // eLife. – 2025. – Vol. 14. – P. e104918. – DOI: 10.7554/eLife.104918.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>5.	Innate immune reprogramming in circulating neutrophils of COPD patients / B. Mariotti [et al.]</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>// Journal of Allergy and Clinical Immunology. – 2025. – [In press].</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>6.	Роль цитокинов IL-4, IL-6, IL-8, IL-10 в иммунопатогенезе хронической обструктивной болезни легких / Е. Ю. Трушина, Е. М. Костина, Б. А. Молотилов [и др.] // Медицинская иммунология. – 2019. – Т. 21, № 1. – URL: https://cyberleninka.ru/article/n/rol-tsitokinov-il-4-il-6-il-8-il-10-v-immunopatogeneze-hronicheskoy-obstruktivnoy-bolezni-legkih (дата обращения: 11.02.2026).</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>7.	Интерлейкин-8 способен поддерживать провоспалительную активность моноцитов (макрофагов) человека / М. Е. Меняйло, В. В. Малащенко, В. А. Шмаров [и др.] // Гены и клетки. – 2018. – Т. XIII, № 1. – С. 42-49. – URL: https://cyberleninka.ru/article/n/interleykin-8-sposoben-podderzhivat-provospalitelnuyu-aktivnost-monotsitov-makrofagov-cheloveka (дата обращения: 11.02.2026).</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>8.	Оценка уровня экспрессии TLR-9 рецепторов при введении препарата Деринат / Д. Ю. Бугримов, Д. В. Лядов, О. Н. Красноруцкая, А. А. Климович // Вестник новых медицинских технологий. – 2012. – Т. XIX, № 2. – С. 102-103. – URL: https://cyberleninka.ru/article/n/otsenka-urovnya-ekspressii-tlr-9-retseptorov-pri-vvedenii-preparata-derinat (дата обращения: 11.02.2026).</mixed-citation></ref></ref-list></back></article>
